Mumbai, India | Slough, UK, August 24, 2021: Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), today announced that following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, it has launched Luforbec® (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.1,2
Luforbec® is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal).3 Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US.
In the twelve months to May 2021, the NHS spent over £177 million on Fostair® 100/6 pMDI.4
About Luforbec® 100/6 pMDI3
Luforbec® is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA)) is appropriate. This includes patients not adequately controlled with ICS and ‘as needed’ inhaled short-acting beta2-agonist or patients already adequately controlled on both ICS and LABA. Luforbec® is indicated for symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.5
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions.5 In FY2021, the Company invested 9.6% of its revenues on research and development.
Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.5
For further information or queries please contact –
Vice President & Head – Corporate Communications
Fostair® is the registered trademark of Chiesi Farmaceutici S.P.A
1 NHS BSA. Drug Tariff. https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff Accessed August 2021.
2 Luforbec 100 micrograms/dose/6 micrograms/dose inhaler. Lupin Healthcare (UK) Ltd. NHS dm+d browser. Available at: https://services.nhsbsa.nhs.uk/dmd-browser/amp/view/162070%20?ref=YW1wTmFtZT1sdW%20ZvcmJlYyZzZWFyY2hUeX%20BlPUFNUA%3D%3D#ampSummary Accessed August 2021
3 Luforbec 100/6 pMDI. Summary of Product Characteristics (SPC). Lupin Healthcare UK Limited. https://www.medicines.org.uk/emc/product/12639/smpc Accessed August 2021
4 General Practice Prescribing Data June 2020 – May 2021 This public sector information is licensed under the Open Government Licence v3.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3). The NHS Business Services Authority (BSA) is the provider of the England data. NHS Wales Shared Partnerships Services is the provider of the Wales data. The Business Services Organisation is the provider of the Northern Ireland data. Public Health Scotland is the provider of the Scotland data
5 IQVIA MAT Dec 2020 https://www.lupin.com/portfolio/lupin-quarter-iii-fy2021-results. Accessed August 2021.